

FOR PATIENTS WITH OVARIAN CANCER

Doxil® is indicated for the treatment of metastatic ovarian cancer in patients with disease that is refractory* to paclitaxel- and platinum-based chemotherapy regimens.

This indication is based on objective tumor response rates. No results are available from controlled trials that demonstrate a clinical benefit resulting from this treatment, such as improvement in disease-related symptoms or increased survival.

*Refractory is defined as disease that has progressed while on treatment, or within 6 months of completing treatment.



DOXIL®: A CONVENIENT CHOICE

THE FLEXIBILITY OF 2 DOSAGE FORMS...

- Simplifies preparation
- Less waste of drug and packaging

...WITH ONLY ONE HCPCS CODE

J9001 doxorubicin hydrochloride, all lipid formulations, 10 mg

Because the HCPCS code represents 10 mg of Doxil®, each 20 mg vial should be billed as 2 units of J9001 and each 50 mg vial should be billed as 5 units.



ORDERING INFORMATION—Doxil® is available in both dosage forms as individually cartoned vials in packages of six.

NDC#: 20 mg vial—#17314-9600-1 50 mg vial—#17314-9600-2

FOR MEDICAL INFORMATION:
1-800-323-9049 or www.alza.com

FOR REIMBURSEMENT INFORMATION:
1-800-609-1083

Please see accompanying brief summary on the following page.



Experience with Doxil® at high cumulative doses is too limited to have established its effects on the myocardium. Therefore, it should be assumed that Doxil® will have myocardial toxicity similar to conventional formulations of doxorubicin HCl. Doxil® should be administered to patients with a history of cardiovascular disease only when the benefit outweighs the risk. Acute infusion-associated reactions have occurred in about 5% to 10% of patients treated with Doxil®. Severe myelosuppression may occur. Dosage should be reduced in patients with impaired hepatic function. Accidental substitution of Doxil® for doxorubicin HCl has resulted in severe side effects. **DO NOT SUBSTITUTE.** The use of Doxil® should be limited to physicians experienced in the use of cancer chemotherapeutic agents.



ALZA Pharmaceuticals
A division of
ALZA Corporation
Mountain View, CA 94043

© 2001 ALZA Corporation